Tag Archives | Biogen

Biogen (BIIB): Proxy Score 47 – Proxy Access Victory

Biogen IdecBiogen Inc. (BIIB) discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It is one of the stocks in my portfolio. Their annual meeting is coming up on 6/10/2015. ProxyDemocracy.org had the vote of five funds (removed 2nd Calvert from table below, since it was duplicative) when I checked and voted on 6/4/2015.  I voted with management 47% of the time and assigned Biogen a proxy score of 47. Continue Reading →

Continue Reading ·

Proxy Access Win at Biogen & Other Efforts in 2015

Proxy Access in the USMy wife and I don’t have the resources to or stock holdings to allow us to file 75 proxy access shareholder proposals, like New York City Comptroller Scott Stringer’s Boardroom Accountability Project. However, I have been writing about proxy access for 20 years and, together with Les Greenberg, filed the petition in 2002 with the SEC that many have credited with renewing interest in the subject. We hope our efforts, although small, contribute to making companies more democratic and profitable. Continue Reading →

Continue Reading ·

Biogen Idec, $BIIB: Proxy Vote

BIIBBiogen Idec, $BIIB, is one of the stocks in my portfolio. Their annual meeting is June 12, 2014. ProxyDemocracy.org had collected the votes of four funds when I checked and voted on 6/10/2014. ProxyDemocracy.org now has collected the votes of five funds.  I voted with management 46% of the time.  View Proxy Statement. Read Warnings below. What follows are my recommendations on how to vote the BIIB proxy in order to enhance corporate governance and long-term value.   Continue Reading →

Continue Reading ·

Powered by WordPress. Designed by WooThemes